Maroney Dawn Christine sold $3.7M of ALHC

Maroney Dawn Christine (President) sold 177,068 shares of Alignment Healthcare, Inc. (ALHC) at $20.83 ($3.69M total) on 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Maroney Dawn Christine
Published Jul 16, 2026, 8:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 16, 2026, 8:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALHC
Neutral
medium confidence
Mentioned
$ALHC
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALHCNeutralLow
01

Why it matters

The disclosure updates the record of insider activity, but it does not introduce new operational, financial, or regulatory information about ALHC.

02

Market read

Traders may monitor insider activity for sentiment, but this specific filing is unlikely to drive a fundamental repricing.

03

What to watch

Insider sales can be offset by other insider buys or option exercises not shown here; also, the filing does not reveal whether future sales are scheduled beyond the current plan.

Relevance 5/10Novelty 3/10Timing: after-hours, following the 2026-07-16 Form 4 filing disclosure

Background

The article is a primary-source SEC Form 4 insider transaction for Alignment Healthcare, Inc. (ALHC).

Company-level read

Ticker impact

$ALHCNeutralMedium confidence
Context

Alignment Healthcare disclosed a Form 4 sale by President Maroney Dawn Christine of 177,068 shares at $20.8281 on 2026-07-15 under a 10b5-1 plan.

Expected impact

Likely limited immediate price impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The filing provides transaction size, price, and 10b5-1 status, but no new company fundamentals, guidance, or regulatory/legal developments.

Market effects

No direct sector read-across; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

The sale could reflect routine liquidity planning rather than negative expectations, especially because it is explicitly under a 10b5-1 plan.

Key entities

  • Alignment Healthcare, Inc.

    Company whose insider transaction was reported on SEC Form 4.

  • Maroney Dawn Christine

    President and reporting officer who sold shares.

  • 10b5-1 plan

    Pre-arranged plan that reduces the interpretive weight of the sale timing.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALHCMedAI 8/10

Alignment Healthcare (ALHC) Q3 2026 Earnings Call Transcript

Alignment Healthcare (ALHC) reported Q3 2026 earnings, with revenue of $1.4B (up 37% YoY) and adjusted gross profit of $142M. The company lowered annual guidance due to higher costs, targeting adjusted gross profit of at least $575M and adjusted EBITDA of $100M. Membership grew 31% YoY to 301,200. ALHC is addressing cost pressures and investing in clinical programs for 2027 growth.

$ALHCMedAI 8/10

What Alignment Healthcare (ALHC) Said on Its Q3 Earnings Call

Alignment Healthcare (ALHC) reduced its 2026 outlook, expecting at least $5.25B revenue, $575M adjusted gross profit, and $100M adjusted EBITDA. Q4 forecasts include 305K membership, $1.32B revenue, and $104M gross profit. Management targets 20% top-line growth in 2027, with plans to enter new markets and improve care model scalability. Stars ratings and provider alignment remain focus areas.